Scientific Reports · 2023 · 10 citations · 41 references
MedicineOncologyPharmacologyDrug DiscoveryMolecular OncologyMolecular PharmacologyDrug Discovery InformaticsOncology PharmacologyStructure-activity Relationship AnalysisSystems Pharmacology In CancerThyroid CancerThyroid EndocrinologyCancer Signaling Network AnalysisChemical Structure-activity RelationshipsDiscoveryEnrichment AnalysisMolecular Docking AnalysisNetwork Diagram AnnotationProtein Expression LevelsWestern Blot Analysis
The aim of the study was to investigated the mechanism of Strychnos nux-vomica L. (Semen Strychni, SS) against papillary carcinoma thyroid (PTC) by combined of network pharmacology and experimental verification. By searching the TCMSP, SEA and SwissTarget Prediction database, the main active ingredients and related targets were obtained. Utilizing Venny 2.1.0 String database and Cytoscape 3.7.2 to screened the intersection target and constructed protein-protein interaction (PPI) network diagram. Using R 4.0.4 software carried out the enrichment analysis of GO and KEGG. HPLC was carried out using LC-20A modular HPLC system to identify the bioactive compound brucine present in SS. Molecular docking was performed using Discovery 2019 software. The inhibition rate was detected by CCK8 method. Western blot was used to detect the expression levels of brucine anti-PTC related pathway proteins. 14 active components were screened out, of which 4 main components showed tight relationship with PTC. SS may play the anti-PTC role by acting on two main pathways (TNF signaling pathway and MAPK signaling pathway) and mediating various biological functions. HPLC analysis revealed that brucine was a suitable marker for standardization of the SS. 4 active components exhibit strong binding energy with core protein. Brucine could significantly reduce the activity of BCPAP cells compared with isobrucine, stigmasterol, (+)-catechin. Brucine may reduce the protein expression levels of IL-6, VEGFA, JUN, TP53, 1L1B, PTGS2, BCL2, CASP3, CASP8, and CASP9 while increase the protein expression levels of BAD, cleaved-CASP3, cleaved-CASP8, and cleaved-CASP9 in BCPAP cells, respectively. The active components of SS against PTC mainly include isobrucine, stigmasterol, (+)-catechin, brucine. Among them, brucine exhibits the strongest anti-PTC activity in BCPAP cells, which may reduce the PTC-related protein expression levels. Therefore, SS may exhibits the anti-PTC activities through multiple targets and pathways.
41
Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks
Paul Shannon, Andrew Markiel, Owen Ozier et al. · Genome Research · 2003 · 54.3K citations · Full text
clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters
Guangchuang Yu, Li-Gen Wang, Yanyan Han et al. · OMICS A Journal of Integrative Biology · 2012 · 38.3K citations
Cancer statistics in China, 2015
Wanqing Chen, Rongshou Zheng, Peter D. Baade et al. · CA A Cancer Journal for Clinicians · 2016 · 18K citations · Full text
Cancer incidence and mortality in China, 2013
Wanqing Chen, Rongshou Zheng, Siwei Zhang et al. · Cancer Letters · 2017 · 499 citations
Medicine, Health Sciences, Oncology +12
Ling Cai, Xijiang Qin, Zhihui Xu et al. · ACS Omega · 2019 · 389 citations · Full text
Medicine, Oncology, Pharmacology +12